An Overview and Trend Analysis of Biosimilar Approvals in China
BioDrugs · 2026-07 · 40 (4) · 599-606
DOI: 10.1007/s40259-026-00788-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 17.06.2026. Verfasst von Mei Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou City, Jiangsu Province, China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Drug Approval. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Biosimilars are a critical strategy for improving access to high-cost biologics and ensuring the sustainability of healthcare systems worldwide. Over the past decade, China has transformed from a nascent market into one of the world’s most active regions for biosimilar development. This review evaluates this transformation with a focus on regulatory evolution, approval dynamics, and global integration. We trace the development of China’s biosimilar regulatory framework from the foundational 2015 Technical Guidelines to the current system of 19 technical and product-specific guidelines, highlighting the maturation of a stepwise, science-driven comparability paradigm aligned with international regulatory standards. Drawing on a systematic analysis of 83 biosimilars approved between 2019 and 2025, we analyze trends across molecular classes, therapeutic areas, and regulatory review pathways, illustrating how regulatory expectations and sponsor development strategies have evolved through representative case examples. Notably, the 2025 annual reports from both the US Food and Drug Administration and European Medicines Agency emphasize the increasing number of biosimilar approvals, therefore, we place China’s approval experience in brief comparative context. Finally, we discuss China’s expanding biosimilar development pipeline in the context of the forthcoming global biologics patent cliff and ongoing international initiatives to streamline biosimilar development, highlighting China’s increasing integration into the global biopharmaceutical landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou City, Jiangsu Province, China.
- Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou City, Jiangsu Province, China. Ning.Zhang02@xjtlu.edu.cn.
- Center for Drug Evaluation, National Medical Products Administration, Beijing, China. wanghx@cde.org.cn.
Zitieren
APA
Yang, M., Zhang, N., & Wang, H. (2026). An Overview and Trend Analysis of Biosimilar Approvals in China. BioDrugs, 40(4), 599-606. https://doi.org/10.1007/s40259-026-00788-8
Vancouver
Yang M, Zhang N, Wang H. An Overview and Trend Analysis of Biosimilar Approvals in China. BioDrugs. 2026;40(4):599-606. doi:10.1007/s40259-026-00788-8
BibTeX
@article{Yang2026,
author = {Yang, Mei and Zhang, Ning and Wang, Haixue},
title = {An Overview and Trend Analysis of Biosimilar Approvals in China},
journal = {BioDrugs},
year = {2026},
volume = {40},
number = {4},
pages = {599--606},
doi = {10.1007/s40259-026-00788-8}
}
EUVIMED